CLDN18.2在晚期胃癌治疗中的临床意义及应用的研究进展
Research Progress on Clinical Significance and Application of CLDN18.2 in the Treatment of Advanced Gastric Cancer
DOI: 10.12677/acm.2025.1582427, PDF,    科研立项经费支持
作者: 陈晨宇：绍兴文理学院医学院，浙江 绍兴；陶克龙*：绍兴文理学院附属第一医院(绍兴市人民医院)胃肠外科，浙江 绍兴
关键词: 胃癌；CLDN18.2；Zolbetuximab；CAR-T；ADC；Gastric Cancer； CLDN18.2； Zolbetuximab； CAR-T； ADC
摘要: 胃癌是消化道常见的恶性肿瘤之一，根据GLOBOCAN 2020年的估计，胃癌造成约80万人死亡(占所有癌症死亡的7.7%)，是男女癌症死亡的第四大原因。在晚期或转移性胃或胃食管交界处腺癌患者中，其中位总生存期仅8~12个月。尽管人类表皮生长因子受体2 (human epidermal growth factor receptor-2, HER-2)靶向治疗为特定人群带来了福音，但由于胃癌细胞具有高度的异质性，曲妥珠单抗(HER2，单克隆抗体)仅对15%~20%的HER2阳性晚期胃癌具有抗肿瘤活性。Claudin18.2是一类存在于上皮和内皮紧密连接中的整合素膜蛋白，是紧密连接的重要组成部分。有研究表明，其在肿瘤的发生发展中具有促进作用。因此，本文就CLDN18.2的结构与功能、在胃癌患者中的分布情况及其在晚期胃癌治疗中的现状加以总结，共同探讨未来发展的方向。
Abstract: Gastric cancer is one of the most prevalent malignant tumors of the digestive tract. According to GLOBOCAN estimates from 2020, gastric cancer accounts for approximately 800,000 deaths (representing 7.7% of all cancer-related fatalities), and it ranks as the fourth leading cause of cancer death among both men and women. In patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, the median overall survival is limited to only 8 to 12 months. While human epidermal growth factor receptor-2 (HER-2) targeted therapy has provided promising outcomes for certain populations, the high heterogeneity of gastric cancer cells means that trastuzumab (HER2, monoclonal antibodies) exhibits antitumor activity in only 15%~20% of HER2-positive advanced gastric cancers. Claudin18.2, an integrin membrane protein found in epithelial and endothelial tight junctions, serves as a crucial component of these junctions. Several studies have demonstrated that it plays a significant role in the occurrence and progression of tumors. Consequently, this article summarizes the structure and function of CLDN18.2, its distribution in gastric cancer patients, and its current status in the treatment of advanced gastric cancer, and jointly discusses the direction of future development.
文章引用：陈晨宇, 陶克龙. CLDN18.2在晚期胃癌治疗中的临床意义及应用的研究进展[J]. 临床医学进展, 2025, 15(8): 1792-1799. https://doi.org/10.12677/acm.2025.1582427

参考文献

[1] Ilic, M. and Ilic, I. (2022) Epidemiology of Stomach Cancer. World Journal of Gastroenterology, 28, 1187-1203. [Google Scholar] [CrossRef] [PubMed]
[2] Zaanan, A. (2022) Immunothérapie dans le traitement du cancer gastrique métastatique. Bulletin du Cancer, 109, 1066-1072. [Google Scholar] [CrossRef] [PubMed]
[3] Nie, S., Yang, G. and Lu, H. (2020) Current Molecular Targeted Agents for Advanced Gastric Cancer. OncoTargets and Therapy, 13, 4075-4088. [Google Scholar] [CrossRef] [PubMed]
[4] Kubota, Y., Kawazoe, A., Mishima, S., Nakamura, Y., Kotani, D., Kuboki, Y., et al. (2023) Comprehensive Clinical and Molecular Characterization of Claudin 18.2 Expression in Advanced Gastric or Gastroesophageal Junction Cancer. ESMO Open, 8, Article 100762. [Google Scholar] [CrossRef] [PubMed]
[5] Breeman, W.A.P., Sze Chan, H., M.S. de Zanger, R., Konijnenberg, M.K. and de Blois, E. (2015) Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT. Current Radiopharmaceuticals, 9, 8-18. [Google Scholar] [CrossRef] [PubMed]
[6] Seregni, E., Maccauro, M., Chiesa, C., Mariani, L., Pascali, C., Mazzaferro, V., et al. (2014) Treatment with Tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of Neuroendocrine Tumours Refractory to Conventional Therapy. European Journal of Nuclear Medicine and Molecular Imaging, 41, 223-230. [Google Scholar] [CrossRef] [PubMed]
[7] Sampaio, I.L., Luíz, H.V., Violante, L.S., Santos, A.P., Antunes, L., Torres, I., et al. (2020) Errata ao artigo “tratamento de tumores neuroendócrinos gastroenteropancreáticos com 177Lu-DOTA-TATE: Experiência do instituto português de Oncologia do Porto”, por Inês Lucena Sampaio, Henrique Vara Luiz, Liliana Sobral Violante, Ana Paula Santos, Luís Antunes, Isabel Torres, Cristina Sanches, Isabel Azevedo, Hugo Duarte publicado em acta med port 2016 Nov;29(11):726-733. Acta Médica Portuguesa, 33, 81-82. [Google Scholar] [CrossRef] [PubMed]
[8] Limouris, G.S., Karfis, I., Chatzioannou, A., et al. (2012) Super-Selective Hepatic Arterial Infusions as Established Technique (‘ARE-TAIEION’ Protocol) of [177Lu] DOTA-TATE in Inoperable Neuroendocrine Liver Metastases of Gastro-Entero-Pancreatic (GEP) Tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 56, 551-558.
[9] Schlingmann, B., Molina, S.A. and Koval, M. (2015) Claudins: Gatekeepers of Lung Epithelial Function. Seminars in Cell & Developmental Biology, 42, 47-57. [Google Scholar] [CrossRef] [PubMed]
[10] Niimi, T., Nagashima, K., Ward, J.M., Minoo, P., Zimonjic, D.B., Popescu, N.C., et al. (2001) Claudin-18, a Novel Downstream Target Gene for the T/EBP/NKX2.1 Homeodomain Transcription Factor, Encodes Lung-and Stomach-Specific Isoforms through Alternative Splicing. Molecular and Cellular Biology, 21, 7380-7390. [Google Scholar] [CrossRef] [PubMed]
[11] Baek, J.H., Park, D.J., Kim, G.Y., Cheon, J., Kang, B.W., Cha, H.J., et al. (2019) Clinical Implications of Claudin18.2 Expression in Patients with Gastric Cancer. Anticancer Research, 39, 6973-6979. [Google Scholar] [CrossRef] [PubMed]
[12] Kyuno, D., Takasawa, A., Takasawa, K., Ono, Y., Aoyama, T., Magara, K., et al. (2021) Claudin-18.2 as a Therapeutic Target in Cancers: Cumulative Findings from Basic Research and Clinical Trials. Tissue Barriers, 10, Article ID: 1967080. [Google Scholar] [CrossRef] [PubMed]
[13] Cao, W., Xing, H., Li, Y., Tian, W., Song, Y., Jiang, Z., et al. (2022) Claudin18.2 Is a Novel Molecular Biomarker for Tumor-Targeted Immunotherapy. Biomarker Research, 10, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[14] Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., et al. (2008) Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clinical Cancer Research, 14, 7624-7634. [Google Scholar] [CrossRef] [PubMed]
[15] Dottermusch, M., Krüger, S., Behrens, H., Halske, C. and Röcken, C. (2019) Expression of the Potential Therapeutic Target Claudin-18.2 Is Frequently Decreased in Gastric Cancer: Results from a Large Caucasian Cohort Study. Virchows Archiv, 475, 563-571. [Google Scholar] [CrossRef] [PubMed]
[16] Rohde, C., Yamaguchi, R., Mukhina, S., Sahin, U., Itoh, K. and Türeci, Ö. (2019) Comparison of Claudin18.2 Expression in Primary Tumors and Lymph Node Metastases in Japanese Patients with Gastric Adenocarcinoma. Japanese Journal of Clinical Oncology, 49, 870-876. [Google Scholar] [CrossRef] [PubMed]
[17] Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., et al. (2019) A Multicentre, Phase Iia Study of Zolbetuximab as a Single Agent in Patients with Recurrent or Refractory Advanced Adenocarcinoma of the Stomach or Lower Oesophagus: The MONO Study. Annals of Oncology, 30, 1487-1495. [Google Scholar] [CrossRef] [PubMed]
[18] Akizuki, R., Eguchi, H., Endo, S., Matsunaga, T. and Ikari, A. (2019) ZO-2 Suppresses Cell Migration Mediated by a Reduction in Matrix Metalloproteinase 2 in Claudin-18-Expressing Lung Adenocarcinoma A549 Cells. Biological and Pharmaceutical Bulletin, 42, 247-254. [Google Scholar] [CrossRef] [PubMed]
[19] Zhang, J., Dong, R. and Shen, L. (2020) Evaluation and Reflection on Claudin 18.2 Targeting Therapy in Advanced Gastric Cancer. Chinese Journal of Cancer Research, 32, 263-270. [Google Scholar] [CrossRef] [PubMed]
[20] Lordick, F., Thuss-Patience, P., Bitzer, M., Maurus, D., Sahin, U. and Türeci, Ö. (2023) Immunological Effects and Activity of Multiple Doses of Zolbetuximab in Combination with Zoledronic Acid and Interleukin-2 in a Phase 1 Study in Patients with Advanced Gastric and Gastroesophageal Junction Cancer. Journal of Cancer Research and Clinical Oncology, 149, 5937-5950. [Google Scholar] [CrossRef] [PubMed]
[21] Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., et al. (2021) FAST: A Randomised Phase II Study of Zolbetuximab (IMAB362) Plus EOX versus EOX Alone for First-Line Treatment of Advanced Cldn18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma. Annals of Oncology, 32, 609-619. [Google Scholar] [CrossRef] [PubMed]
[22] Couzin-Frankel, J. (2013) Breakthrough of the Year 2013. Cancer Immunotherapy. Science, 342, 1432-1433. [Google Scholar] [CrossRef] [PubMed]
[23] Baker, D.J., Arany, Z., Baur, J.A., Epstein, J.A. and June, C.H. (2023) CAR T Therapy Beyond Cancer: The Evolution of a Living Drug. Nature, 619, 707-715. [Google Scholar] [CrossRef] [PubMed]
[24] Jiang, H., Shi, Z., Wang, P., Wang, C., Yang, L., Du, G., et al. (2018) Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. JNCI: Journal of the National Cancer Institute, 111, 409-418. [Google Scholar] [CrossRef] [PubMed]
[25] Xu, R., Ruan, D., Zhang, D., Liu, F., Luo, S., Zhuang, Z., et al. (2023) A Phase 1 Trial of Claudin 18.2-Specific Antibody-Drug Conjugate CMG901 in Patients with Advanced Gastric/Gastroesophageal Junction Cancer. Journal of Clinical Oncology, 41, 434420-434420. [Google Scholar] [CrossRef] 
[26] Wang, Y., Gong, J., Lin, R., Zhao, S., Wang, J., Wang, Q., et al. (2023) First-in-Human Dose Escalation and Expansion Study of SYSA1801, an Antibody-Drug Conjugate Targeting Claudin 18.2 in Patients with Resistant/Refractory Solid Tumors. Journal of Clinical Oncology, 41, 3016-3016. [Google Scholar] [CrossRef] 
[27] Zhu, G., Foletti, D., Liu, X., Ding, S., Melton Witt, J., Hasa-Moreno, A., et al. (2019) Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Scientific Reports, 9, Article No. 8420. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, S., Qi, C., Ding, J., Li, D., Zhang, M., Ji, C., et al. (2023) First-in-Human CLDN18.2 Functional Diagnostic Pet Imaging of Digestive System Neoplasms Enables Whole-Body Target Mapping and Lesion Detection. European Journal of Nuclear Medicine and Molecular Imaging, 50, 2802-2817. [Google Scholar] [CrossRef] [PubMed]
[29] Hu, G., Zhu, W., Liu, Y., Wang, Y., Zhang, Z., Zhu, S., et al. (2022) Development and Comparison of Three 89zr-Labeled Anti-CLDN18.2 Antibodies to Noninvasively Evaluate CLDN18.2 Expression in Gastric Cancer: A Preclinical Study. European Journal of Nuclear Medicine and Molecular Imaging, 49, 2634-2644. [Google Scholar] [CrossRef] [PubMed]
[30] Chen, Y., Hou, X., Li, D., Ding, J., Liu, J., Wang, Z., et al. (2023) Development of a CLDN18.2-Targeting Immuno-Pet Probe for Non-Invasive Imaging in Gastrointestinal Tumors. Journal of Pharmaceutical Analysis, 13, 367-375. [Google Scholar] [CrossRef] [PubMed]
[31] Qi, C., Guo, R., Chen, Y., Li, C., Liu, C., Zhang, M., et al. (2024) 68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients. Journal of Nuclear Medicine, 65, 856-863. [Google Scholar] [CrossRef] [PubMed]
[32] Zhong, W., Lu, Y., Ma, Z., He, Y., Ding, Y., Yao, G., et al. (2022) Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Frontiers in Immunology, 13, Article 885424. [Google Scholar] [CrossRef] [PubMed]

为你推荐